Journal articleJ Genet Eng Biotechnol2025
Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.
- Journal
- J Genet Eng Biotechnol
- Published
- 17 February 2025
- Citations
- 6
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract CC BY
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC’s dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.
financial support CC BY
The authors did not receive any financial contribution for this research.
credit authorship contribution statement CC BY
Aariz Hussain: Writing – review & editing, Writing – original draft. Areeba Fareed: Writing – review & editing, Writing – original draft.
ethics approval CC BY
ERB Approval was not required for this research.
declaration of competing interest CC BY
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.